Business Segments Telix Pharmaceuticals Limited

Stocks

Market Closed - Australian S.E. Other stock markets 11:40:15 13/07/2026 am IST			5-day change	1st Jan Change
15.99 ^AUD	-1.72%		-5.27%	+42.77%

10/07	ASX Biggest Losers	MT
03/07	Telix Pharmaceuticals Securing FDA Nod in Line With Expectations, Says Jefferies, Shares Down 3%	MT

Breakdown by Business Segment (AUD)

Fiscal Period: December	2021	2022	2023	2024	2025 (USD)
Biological Products
Precision Medicine	-	-	-	77Cr	62Cr
Total Assets	-	-	-	48Cr	23Cr
Gross Profit	-	-	-	50Cr	40Cr
EBITDA	-	-	-	26Cr	22Cr
D&A	-	-	-	55.73L	33.33L
Operating Income	-	-	-	24Cr	21Cr
Manufacturing Solutions	-	-	-	27.5L	25Cr
Total Assets	-	-	-	22Cr	52Cr
Gross Profit	-	-	-	42T	2.23Cr
EBITDA	-	-	-	-2.39Cr	-2.17Cr
D&A	-	-	-	12.93L	1.69Cr
Operating Income	-	-	-	-2.5Cr	-2.39Cr
Therapeutics	-	-	-	93.51L	92.73L
Total Assets	-	-	-	22Cr	23Cr
Gross Profit	-	-	-	93.51L	90.44L
EBITDA	-	-	-	-7.35Cr	-9.8Cr
D&A	-	-	-	-	3L
Operating Income	-	-	-	-7.35Cr	-9.83Cr
Product Development	-	37.27L	54.96L	-	-
Total Assets	-	4.43Cr	4.67Cr	-	-
EBT	-	-7.66Cr	-12Cr	-	-
Gross Profit	-	-	54.96L	-	-
EBITDA	-	-7.6Cr	-12Cr	-	-
D&A	-	6L	5L	-	-
Operating Income	-	-	-12Cr	-	-
Net Income	-	-7.66Cr	-12Cr	-	-
Commercial	-	16Cr	50Cr	-	-
Total Assets	-	11Cr	29Cr	-	-
Income Tax Expense	-	57.07L	-	-	-
EBT	-	3.42Cr	22Cr	-	-
Gross Profit	-	-	31Cr	-	-
EBITDA	-	3.96Cr	22Cr	-	-
D&A	-	46.1L	56.65L	-	-
Operating Income	-	-	22Cr	-	-
Net Income	-	2.85Cr	22Cr	-	-
Pharmaceuticals	75.96L	-	-	-	-
Total Assets	11Cr	-	-	-	-
Interest Expense	-2L	-	-	-	-
Income Tax Expense	45T	-	-	-	-
CAPEX	-13.39L	-	-	-	-
EBT	-8.05Cr	-	-	-	-
Gross Profit	-	-	-	-	-
D&A	51.74L	-	-	-	-
Net Income	-8.05Cr	-	-	-	-
Inter-Segment Elimination	-	-	-	-	-7.25Cr
Gross Profit	-	-	-	-	-40.38L
EBITDA	-	-	-	-	-3L
Operating Income	-	-	-	-	-3L
Total Assets	-	-	-	60Cr	19Cr
Operating Income	-	-	-7.84Cr	-	-
Net Income	-	-5.6Cr	-8.9Cr	-	-
D&A	-	2L	5L	-	-
EBITDA	-	-3.14Cr	-4.28Cr	-	-
EBT	-	-5.62Cr	-9.11Cr	-	-
Income Tax Expense	-	-2L	-	-	-
Total Assets	-	9.95Cr	6.31Cr	-	-

Geographical breakdown of sales (AUD)

Fiscal Period: December	2021	2022	2023	2024	2025 (USD)
United States	-	15Cr	49Cr	76Cr	78Cr
Total Assets	-	51.6L	41.3L	17Cr	48Cr
China	-	33.53L	52.91L	-	98.34L
Other Countries	-	24.96L	46.69L	1.6Cr	90.55L
Total Assets	-	-	-	48.52L	82.45L
Canada	-	-	-	25.42L	-
Total Assets	-	-	-	13Cr	8.66Cr
United Kingdom	-	20.45L	13.06L	6L	-
Total Assets	-	-	5.03Cr	5.46Cr	3.71Cr
Belgium	-	6L	5L	5L	-
Total Assets	-	4.12Cr	7.75Cr	10Cr	5.95Cr
Austria	-	14.83L	-	-	-
Australia	75.96L	1L	11.66L	12.2L	-
Total Assets	11Cr	3.18Cr	2.11Cr	9.1Cr	10Cr
Interest Expense	-2L	-	-	-	-
Income Tax Expense	45T	-	-	-	-
D&A	51.74L	-	-	-	-
CAPEX	-13.39L	-	-	-	-
Gross Profit	-	-	-	-	-
Net Income	-8.05Cr	-	-	-	-
EBT	-8.05Cr	-	-	-	-